跳至主要内容
临床试验/DRKS00023167
DRKS00023167暂停不适用

Clinical testing of a new, CE-certified joint mechanism (MUTARS® HD coupling C-O-M) for the implantation of a tumour or revision prosthesis in the area of the knee joint - MUTARS HD C-O-M

niversitätsklinikum Essen0 个研究点目标入组 175 人开始时间: 2020年10月19日最近更新:
适应症

试验速览

阶段
不适用
状态
暂停
发起方
入组人数
175

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • 1. Patients for which a tumour prosthesis of the proximal tibia or the type MUTARS® total knee, as well as MUTARS® distal femur, needs to be implanted. Indication for tumorresection and reconstruction is also given within the sarcoma-tumor-conference.
  • 1.Patients are included for which a replacement operation to a revision endoprosthesis type GenuX® MK or KRI or instead to the systems MUTARS® proximal tibia or MUTARS® femur is necessary due to failure (e.g. infection, loosening, perioperative fracture) of a previously implanted knee endoprosthesis.

排除标准

  • Patients without any indication for implantation of tumor prosthesis (decision of tumor conference) in case of sarcoma or metastasis. Furthermore excluded are patients without any need to implant an axis-guided prosthesis in case of revision surgery.

研究者

发起方
niversitätsklinikum Essen

相似试验